BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 12964069)

  • 1. Lapatinib ditosylate GlaxoSmithKline.
    Kim TE; Murren JR
    IDrugs; 2003 Sep; 6(9):886-93. PubMed ID: 12964069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BAY-43-9006 Bayer/Onyx.
    Lee JT; McCubrey JA
    Curr Opin Investig Drugs; 2003 Jun; 4(6):757-63. PubMed ID: 12901237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BMS-247550 Bristol-Myers Squibb/GBF.
    Lin N; Brakora K; Seiden M
    Curr Opin Investig Drugs; 2003 Jun; 4(6):746-56. PubMed ID: 12901236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 109881 Aventis.
    Ojima I; Geney R
    Curr Opin Investig Drugs; 2003 Jun; 4(6):737-40. PubMed ID: 12901234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.
    Nelson MH; Dolder CR
    Ann Pharmacother; 2006 Feb; 40(2):261-9. PubMed ID: 16418322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MEN-10755. Menarini.
    Jones K
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1473-8. PubMed ID: 14763135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZD-6126 AstraZeneca.
    Soltau J; Drevs J
    IDrugs; 2004 Apr; 7(4):380-7. PubMed ID: 15057644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lerisetron. FAES.
    Huckle R
    Curr Opin Investig Drugs; 2003 Jul; 4(7):874-7. PubMed ID: 14619411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CKD-602. Chong Kun Dang.
    Crul M
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1455-9. PubMed ID: 14763132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CMT-3. CollaGenex.
    Fingleton B
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1460-7. PubMed ID: 14763133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arzoxifene Eli Lilly.
    Marchisano-Karpman C; DeGregorio MW
    IDrugs; 2003 Sep; 6(9):880-5. PubMed ID: 12964068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.
    Burris HA
    Oncologist; 2004; 9 Suppl 3():10-5. PubMed ID: 15163842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diflomotecan. Ipsen.
    Osheroff N
    IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
    [No Abstract]   [Full Text] [Related]  

  • 15. TLK-286.
    Verschraegen CF; Smith HO; Lee FC; Cathcart C; Norenberg JP
    IDrugs; 2004 Aug; 7(8):771-81. PubMed ID: 15334311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AE-941 (AEterna).
    Dredge K
    Curr Opin Investig Drugs; 2004 Jun; 5(6):668-77. PubMed ID: 15242256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Halterman PA
    Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ganstigmine. Chiesi.
    Johnson A
    Curr Opin Investig Drugs; 2003 Jul; 4(7):868-73. PubMed ID: 14619410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib-associated toxicity and practical management recommendations.
    Moy B; Goss PE
    Oncologist; 2007 Jul; 12(7):756-65. PubMed ID: 17673607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nemifitide. Innapharma.
    Dingemanse J
    Curr Opin Investig Drugs; 2003 Jul; 4(7):859-62. PubMed ID: 14619408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.